InnovAge vs Pennant
INNV and PNTG side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How INNV and PNTG compare
InnovAge and Pennant are about the same size, with market caps of $1.3B and $1.3B.
Pennant grew revenue faster over the last twelve months (38.7% versus 15.9% for InnovAge).
Pennant keeps more of each dollar of sales as profit, with a net margin of 3.1% compared with −0.26% at InnovAge.
Pennant scores higher on the StockData Score (14 against 10 for InnovAge), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | INNV | PNTG |
|---|---|---|
| Size and price | ||
| Market cap | $1.3B | $1.3B |
| Share price | $9.47 | $36.07 |
| Change, 1 year | 66.4% | 42.9% |
| Change, 5 years | 12.6% | 60.2% |
| Beta (5Y) | 0.68 | 1.06 |
| Employees | 2,500 | 9,700 |
| StockData Score | ||
| Total score | 10 | 14 (better) |
| Valuation score | 0 | 4 (better) |
| Growth score | 3 | 4 (better) |
| Performance score | 2 | 3 (better) |
| Health score | 5 (better) | 3 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 36.4× |
| P/S | 1.3× | 1.1× (better) |
| P/B | 5.5× | – |
| EV/EBITDA | 50.6× | 16.1× (better) |
| P/FCF | 25.6× (better) | 36.7× |
| PEG | – | 0.65 |
| FCF yield | 3.9% (better) | 2.7% |
| Fair value | $5.76 | $37.49 |
| Margin of safety | −64.3% | 3.8% (better) |
| Growth | ||
| Revenue growth (TTM) | 15.9% | 38.7% (better) |
| Revenue growth, 5Y average | 9.2% | 19.4% (better) |
| Net income growth (TTM) | – | 34.4% |
| EPS growth (TTM) | – | 32.0% |
| EPS growth, 5Y average | – | 10.1% |
| Profitability | ||
| Gross margin | 23.0% (better) | 18.3% |
| Operating margin | 0.26% | 5.8% (better) |
| Net margin | −0.26% | 3.1% (better) |
| FCF margin | 5.1% (better) | 2.9% |
| Return on equity | −1.1% | – |
| Return on invested capital | 1.2% | – |
| Financial health | ||
| Debt / equity | 0.20 | – |
| Net debt / EBITDA | −3.93 | −0.17 |
| Interest coverage | – | 5.2× |
| Current ratio | 1.05 | 1.18 (better) |
| Altman Z-score | 4.23 (better) | 2.74 |
| Piotroski F-score | 6 (better) | 5 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 13.5% | 92.7% |
| Held by insiders | 75.4% | 5.0% |
| Insider net buying, 12 months | −$227M | −$690K (better) |
| Short interest, % of float | 2.7% | 3.5% |
Go deeper
- INNV stock overview
- INNV income statement
- INNV valuation and score
- PNTG stock overview
- PNTG income statement
- PNTG valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.